Last reviewed · How we verify

Imatinib Mesylate and Nilotinib

University Hospital, Lille · Phase 3 active Small molecule

Imatinib Mesylate and Nilotinib is a Tyrosine kinase inhibitor Small molecule drug developed by University Hospital, Lille. It is currently in Phase 3 development for Chronic myeloid leukemia (CML), chronic phase, CML with BCR-ABL mutations or imatinib resistance. Also known as: Gleevec, Tasigna.

Imatinib and nilotinib are tyrosine kinase inhibitors that block BCR-ABL and other oncogenic kinases to suppress abnormal cell proliferation in chronic myeloid leukemia.

Imatinib and nilotinib are tyrosine kinase inhibitors that block BCR-ABL and other oncogenic kinases to suppress abnormal cell proliferation in chronic myeloid leukemia. Used for Chronic myeloid leukemia (CML), chronic phase, CML with BCR-ABL mutations or imatinib resistance.

At a glance

Generic nameImatinib Mesylate and Nilotinib
Also known asGleevec, Tasigna
SponsorUniversity Hospital, Lille
Drug classTyrosine kinase inhibitor
TargetBCR-ABL
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Both drugs inhibit the BCR-ABL fusion protein tyrosine kinase, which drives chronic myeloid leukemia (CML) pathogenesis. Imatinib was the first-generation inhibitor, while nilotinib is a second-generation inhibitor with improved potency and selectivity. The combination or sequential use may be evaluated in Phase 3 trials to overcome resistance or improve efficacy in CML patients.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Imatinib Mesylate and Nilotinib

What is Imatinib Mesylate and Nilotinib?

Imatinib Mesylate and Nilotinib is a Tyrosine kinase inhibitor drug developed by University Hospital, Lille, indicated for Chronic myeloid leukemia (CML), chronic phase, CML with BCR-ABL mutations or imatinib resistance.

How does Imatinib Mesylate and Nilotinib work?

Imatinib and nilotinib are tyrosine kinase inhibitors that block BCR-ABL and other oncogenic kinases to suppress abnormal cell proliferation in chronic myeloid leukemia.

What is Imatinib Mesylate and Nilotinib used for?

Imatinib Mesylate and Nilotinib is indicated for Chronic myeloid leukemia (CML), chronic phase, CML with BCR-ABL mutations or imatinib resistance.

Who makes Imatinib Mesylate and Nilotinib?

Imatinib Mesylate and Nilotinib is developed by University Hospital, Lille (see full University Hospital, Lille pipeline at /company/university-hospital-lille).

Is Imatinib Mesylate and Nilotinib also known as anything else?

Imatinib Mesylate and Nilotinib is also known as Gleevec, Tasigna.

What drug class is Imatinib Mesylate and Nilotinib in?

Imatinib Mesylate and Nilotinib belongs to the Tyrosine kinase inhibitor class. See all Tyrosine kinase inhibitor drugs at /class/tyrosine-kinase-inhibitor.

What development phase is Imatinib Mesylate and Nilotinib in?

Imatinib Mesylate and Nilotinib is in Phase 3.

What are the side effects of Imatinib Mesylate and Nilotinib?

Common side effects of Imatinib Mesylate and Nilotinib include Nausea, Vomiting, Diarrhea, Muscle cramps, Rash, Edema.

What does Imatinib Mesylate and Nilotinib target?

Imatinib Mesylate and Nilotinib targets BCR-ABL and is a Tyrosine kinase inhibitor.

Related